Healey: No tolls on Cape bridges
Mashpee Select Board Vice Chair David Weeden floated the idea at a meeting Monday.
'I'd advocate for tolls to be imposed at the bridges,' Weeden said. 'Over 35 million vehicles come across those two bridges combined annually. Even if you did $2 an axle, only calculating cars, you'd bring in about $70 million a year. That money should be earmarked specifically to leverage [state revolving fund] funds and go towards coastal and water quality issues.'
Weeden suggested the state could look into just tolling people coming from off-Cape, using EZ Pass technology to identify residents so they could get on and off the bridges without paying tolls.
'Massachusetts reaps the benefits of Cape Cod tourism, and it's a significant amount of money that comes into the state through the tourism that we receive here, and on the Cape they come over here and they leave their stuff behind, and then we're left to deal with it. So, you know, charging a modest rate,' Weeden said.
Asked about the idea after an unrelated event at the State House on Wednesday, Healey immediately shot it down.
'I don't support the tolls on the bridges,' she said.
Healey talked about her administration's efforts to replace the Bourne and Sagamore bridges. The Healey administration is eyeing 2027 to start work, beginning with the Sagamore Bridge, though the state has so far only secured just half of the two-bridge project's more than $4.5 billion price tag.
'I hope to make continued progress on the bridges,' Healey said. 'That's been something that we've prioritized, to move ahead on. But, no tolls on the bridges.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). The regulatory body granted accelerated approval to linvoseltamab under the brand name Lynozyfic for the treatment of R/R MM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti CD38 monoclonal antibody. Lynozyfic is a fully human BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. Year to date, REGN's shares have lost 22.9% compared with the industry's 0.6% decline. Image Source: Zacks Investment Research The approval was based on positive results from the phase I/II LINKER-MM1 trial, wherein Lynozyfic demonstrated one of the highest objective response rates (70%) and complete response rates (45%) among bispecific antibodies for this challenging patient population. With the FDA approval, Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy. MM remains the second most common blood cancer, with more than 36,000 new cases expected in the US in 2025 is tailored for patients who have undergone at least four prior treatment regimens, addressing a critical unmet need in late-stage MM. The approval strengthens REGN's oncology portfolio. Lynozyfic is also approved in the European Union to treat adults with R/R MM after at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. We note that the FDA had earlier issued a CRL for the BLA for linvoseltamab in R/R multiple myeloma. The sole approvability issue identified was related to findings from a pre-approval inspection at a third-party fill/finish manufacturer. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote REGN is currently looking to strengthen its oncology franchise, which currently comprises Libtayo, indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer. REGN's oncology franchise received a boost with the European Commission's approval of odronextamab in 2024 for treating adult patients with R/R follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The drug has been approved under the brand name Ordspono. However, the company's efforts to get odronextamab approved in the United States suffered a setback. The regulatory body issued CRLs for its BLA for odronextamab in 2024. The FDA has accepted for review the resubmission of the BLA for odronextamab in R/R follicular lymphoma with a target action date of July 30, 2025. The successful development of these oncology drugs should be a great boost for REGN. The decline in lead drug Eylea sales is a concern for REGN. Eylea sales are under pressure due to competition from Roche's RHHBY Vabysmo. Roche designed Vabysmo to block pathways involving Ang-2 and VEGF-A. The uptake of Vabysmo has been outstanding, causing a loss of market share for Eylea. REGN currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Bayer BAYRY, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.69 to $8.81 over the past 60 days. EPS estimates for 2026 have jumped 12 cents to $9.12 during this time frame. The stock has risen 30.2% so far this year. BAYRY's 2025 EPS estimate has increased from $1.19 to $1.25 over the past 90 days, while that for 2026 has gone up from $1.28 to $1.31 over the same time frame. Year to date, shares of Bayer have surged 60%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
30 minutes ago
- Business Wire
Helix Announces Second Quarter Earnings Release Date and Conference Call Information
HOUSTON--(BUSINESS WIRE)--Helix Energy Solutions Group, Inc. (NYSE: HLX) will issue a press release reporting its second quarter 2025 results on Wednesday, July 23, 2025, after the close of business. The press release and associated slide presentation will be available on Helix's website, Helix will review its second quarter 2025 results on Thursday, July 24, 2025, at 9:00 a.m. Central Time via a teleconference and webcast. Investors and other interested parties wishing to participate should dial 1-800-715-9871 within the United States or 1-646-307-1963 outside the United States. The passcode is "Staffeldt." A live webcast of the teleconference will be available in a listen-only mode on the Investor Relations section of Helix's website. A replay of the webcast will be available on Helix's website shortly after the completion of the event. About Helix Helix Energy Solutions Group, Inc., headquartered in Houston, Texas, is an international offshore energy services company that provides specialty services to the offshore energy industry, with a focus on well intervention, robotics and decommissioning operations. Our services are key in supporting a global energy transition by maximizing production of existing oil and gas reserves, decommissioning end-of-life oil and gas fields and supporting renewable energy developments. For more information about Helix, please visit our website at
Yahoo
an hour ago
- Yahoo
GEO Group Secures $147M Contract with U.S. Marshals for Secure Transport Services
The GEO Group, Inc. (NYSE:GEO) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 16, the U.S. Marshals Service granted GEO Transport, a subsidiary of the The GEO Group, Inc. (NYSE:GEO), a new five-year contract for secure transportation and detention officer services. The agreement covers 26 federal judicial districts in 14 states, with three service zones covered. According to the company's statement, the contract is expected to earn up to $147 million over the period, or roughly $29 million in annualized revenue. According to the company, profit margins for this contract should be comparable to those of its Managed-Only services contracts, which normally have an average of 15%. George C. Zoley, Executive Chairman of GEO, stated the following regarding the new agreement: 'This important new contract is a testament to the high-quality services GEO delivers on behalf of the U.S. Marshals Service.' The GEO Group, Inc. (NYSE:GEO) identifies as a diversified government service provider with a focus on community reintegration centers, processing centers, and secure institutions. The company is divided into four sections: International Services, Reentry Services, Electronic Monitoring & Supervision Services, and US Secure Services. While we acknowledge the potential of GEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
